Mesa Laboratories, Inc. (MLAB) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

BioLife Solutions, Inc.

IRadimed Corp.

Artivion, Inc.

Mesa Laboratories, Inc.

Silk Road Medical, Inc.

OrthoPediatrics Corp.

Atrion Corp.

Cytek Biosciences, Inc.

Varex Imaging Corp.

Nevro Corp.

Minerva Surgical, Inc.

Why is Mesa Laboratories, Inc. ?

The company is Net-Debt Free

Positive results in Mar 26

NET PROFIT(HY) Higher at USD -0.51 MM
ROCE(HY) Highest at 3.88%
DEBT-EQUITY RATIO (HY) Lowest at 76.19 %

With ROCE of 5.26%, it has a fair valuation with a 1.81 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 2.27%, its profits have fallen by -84.2%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Underperformed the market in the last 1 year

The stock has generated a return of 2.27% in the last 1 year, much lower than market (S&P 500) returns of 25.41%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Mesa Laboratories, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Mesa Laboratories, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Mesa Laboratories, Inc.

2.27%

-0.08

63.96%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.72%

EBIT Growth (5y)

6.39%

EBIT to Interest (avg)

1.25

Debt to EBITDA (avg)

3.77

Net Debt to Equity (avg)

0.96

Sales to Capital Employed (avg)

0.61

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

2.60%

ROE (avg)

3.49%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

121

Industry P/E

Price to Book Value

2.43

EV to EBIT

34.50

EV to EBITDA

14.07

EV to Capital Employed

1.81

EV to Sales

2.40

PEG Ratio

Dividend Yield

ROCE (Latest)

5.26%

ROE (Latest)

2.00%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET PROFIT(HY)

Higher at USD -0.51 MM

ROCE(HY)

Highest at 3.88%

DEBT-EQUITY RATIO (HY)

Lowest at 76.19 %

INVENTORY TURNOVER RATIO(HY)

Highest at 4.18 times

RAW MATERIAL COST(Y)

Fallen by -14.45% (YoY

-14What is not working for the Company

NET PROFIT(Q)

At USD -4.14 MM has Fallen at -543.06%

OPERATING CASH FLOW(Y)

Lowest at USD 42.82 MM

INTEREST COVERAGE RATIO(Q)

Lowest at 327.35

CASH AND EQV(HY)

Lowest at USD 55.9 MM

OPERATING PROFIT(Q)

Lowest at USD 8.5 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 13.34 %

PRE-TAX PROFIT(Q)

Lowest at USD -1.59 MM

Here's what is working for Mesa Laboratories, Inc.

Debt-Equity Ratio

Lowest at 76.19 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 4.18 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -14.45% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Mesa Laboratories, Inc.

Pre-Tax Profit

At USD -1.59 MM has Fallen at -145.29%

over average net sales of the previous four periods of USD 3.52 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -4.14 MM has Fallen at -543.06%

over average net sales of the previous four periods of USD 0.93 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest Coverage Ratio

Lowest at 327.35

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Operating Cash Flow

Lowest at USD 42.82 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD 8.5 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at 13.34 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at USD -1.59 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Cash and Eqv

Lowest at USD 55.9 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents